Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients.

Journal article

Lubrano E. et al, (2019), Rheumatol ther

Gender equity in clinical practice, research and training: Where do we stand in rheumatology?

Journal article

Andreoli L. et al, (2019), Joint bone spine

Best-practice Indicators in Psoriatic Disease Care.

Journal article

Helliwell PS. et al, (2019), J rheumatol suppl, 95, 38 - 45

EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY

Conference paper

Coates LC. et al, (2019), Annals of the rheumatic diseases, 78, 1269 - 1270

EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY

Conference paper

Mease PJ. et al, (2019), Annals of the rheumatic diseases, 78, 128 - 128

GRAPPA 2018 Project Report.

Journal article

Goel N. et al, (2019), J rheumatol suppl, 95, 54 - 57

NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAIVE, SYSTEMIC THERAPY-NAIVE) PSORIATIC DISEASE: A SYSTEMATIC REVIEW

Conference paper

De Marco G. et al, (2019), Annals of the rheumatic diseases, 78, 904 - 904

PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY

Conference paper

Orbai A-M. et al, (2019), Annals of the rheumatic diseases, 78, 1265 - 1266

Load More